Log in to save to my catalogue

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2049945150

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Among patients with
IDH1
-mutated relapsed or refractory leukemia, daily oral ivosidenib, an IDH1 inhibitor, induced molecular clearance of leukemic cells from bone marrow in 21% of patients and was associated with transfusion independence and a low rate of serious adverse events.

Alternative Titles

Full title

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2049945150

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2049945150

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1716984

How to access this item